Download PDF
Am J Perinatol
DOI: 10.1055/a-2496-2310
Original Article

Prospective Cohort Study Investigating Polyunsaturated Fatty Acids and Chronic Lung Disease in Preterm Infants

Teryn Igawa
1   Department of Pediatrics, Children's Discovery and Innovation Institute, David Geffen School of Medicine UCLA and UCLA Mattel Children's Hospital, Los Angeles
,
Tessa C. Gillespie
2   Department of Pediatrics, Stanford University and Stanford Medicine, Palo Alto, California
,
Esther S. Kim
3   Division of Neonatology, Department of Pediatrics, UCLA – Olive View, Sylmar, California
,
Lauren J. Lee
4   Department of Pediatrics, Harvard Medical School and Boston Children's Hospital, Boston, Massachusetts
,
Tristan Grogan
5   Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California
6   Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, UCLA, Los Angeles, California
,
Alison Chu
1   Department of Pediatrics, Children's Discovery and Innovation Institute, David Geffen School of Medicine UCLA and UCLA Mattel Children's Hospital, Los Angeles
,
Kara L. Calkins 
1   Department of Pediatrics, Children's Discovery and Innovation Institute, David Geffen School of Medicine UCLA and UCLA Mattel Children's Hospital, Los Angeles
› Author Affiliations Funding T.C.G. received funding from the Short Term Training Program, David Geffen School of Medicine. E.S.K. received funding from T32 EY007026 and the UCLA Children's Discovery and Innovation Institute. A.C. is funded by NIH/NEI R01EY032561. K.L.C. received funding from NIH/NCATS KL2TR000122. Statistical analyses for this research was supported in part by NIH National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR001881.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective Chronic lung disease (CLD) is a complication of prematurity. Studies examining the effects of long-chain polyunsaturated fatty acids (LC-PUFAs) on CLD are conflicting. This study investigated LC-PUFAs in the red blood cell membrane (RBCM) in preterm infants.

Study Design This prospective observational study included infants with gestational age <32 weeks or birth weight <2 kg and at least one LC-PUFA measurement in the first month of life. Subjects without CLD (CON group) were compared with those with CLD (CLD group) and then by CLD severity.

Results Seventy infants were included (CON n = 29; CLD n = 41). Twenty-six infants had Grade 1 CLD; 12 had Grade 2 CLD; 3 had Grade 3 CLD. When the CLD group was compared with the CON group, the overall mean (95% confidence interval) RBCM% for linoleic acid (LA) was similar (CLD vs. CON 12.5% [11.7–13.4%] vs. 11.2% [10.2–12.3%], p = 0.06) but the overall mean arachidonic acid (ARA) was lower (17.6% [17.1–18.0%] vs. 18.6% [18.1–19.2%], p < 0.01). During weeks 1 to 4, LA% was similar, while ARA% was lower in weeks 2 and 3 (18.8 ± 2.2% vs. 20.0 ± 1.5%, p = 0.05, 16.8 ± 2.0% vs. 18.3 ± 1.6%, p = 0.01). A similar trend was noted when groups were compared by CLD severity. The CLD group had a higher overall mean α-linolenic acid (ALA) compared with the CON group (0.4% [0.3–0.4%] vs. 0.2% [0.2–0.3%], p < 0.01) but no difference in docosahexaenoic acid (DHA; 3.8% [3.4–4.1%] vs. 3.8% [3.4–4.3%], p = 0.80). During weeks 1 to 4, ALA% was higher during week 1 only (0.4 ± 0.3% vs. 0.2 ± 0.1%, p < 0.01), and DHA% was similar for weeks 1 to 4. Results were similar when groups were compared by CLD severity.

Conclusion In this study, low ARA status was associated with CLD.

Key Points

  • In this study, infants with CLD had a similar RBCM% of LA, but a lower percentage of its downstream LC-PUFA, ARA, compared with infants without CLD.

  • In this study, infants with CLD had a higher RBCM% of α-linolenic acid, but a similar percentage of its downstream LC-PUFA, DHA, compared with infants without CLD.

  • In this study, these trends were similiar when groups were compared by CLD severity.

Keywords

chronic lung disease - long-chain polyunsaturated fatty acids - nutrition - preterm - infant


Publication History

Received: 10 September 2024

Accepted: 03 December 2024

Accepted Manuscript online:
05 December 2024

Article published online:
09 January 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Jensen EA, Dysart K, Gantz MG. et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. Am J Respir Crit Care Med 2019; 200 (06) 751-759
    CrossrefPubMedSearch in Google Scholar
  • 2 Principi N, Di Pietro GM, Esposito S. Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies. J Transl Med 2018; 16 (01) 36
    CrossrefPubMedSearch in Google Scholar
  • 3 Tam EW, Chau V, Barkovich AJ. et al. Early postnatal docosahexaenoic acid levels and improved preterm brain development. Pediatr Res 2016; 79 (05) 723-730
    CrossrefPubMedSearch in Google Scholar
  • 4 Gould JF, Makrides M, Gibson RA. et al. Neonatal docosahexaenoic acid in preterm infants and intelligence at 5 years. N Engl J Med 2022; 387 (17) 1579-1588
    CrossrefPubMedSearch in Google Scholar
  • 5 Wang Q, Zhou B, Cui Q, Chen C. Omega-3 long-chain polyunsaturated fatty acids for bronchopulmonary dysplasia: a meta-analysis. Pediatrics 2019; 144 (01) e20190181
    CrossrefPubMedSearch in Google Scholar
  • 6 Innis SM. Omega-3 Fatty acids and neural development to 2 years of age: do we know enough for dietary recommendations?. J Pediatr Gastroenterol Nutr 2009; 48 (Suppl. 01) S16-S24
    PubMedSearch in Google Scholar
  • 7 Collins CT, Makrides M, McPhee AJ. et al. Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants. N Engl J Med 2017; 376 (13) 1245-1255
    CrossrefPubMedSearch in Google Scholar
  • 8 Thébaud B, Goss KN, Laughon M. et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers 2019; 5 (01) 78
    CrossrefPubMedSearch in Google Scholar
  • 9 Shrestha N, Sleep SL, Cuffe JSM. et al. Role of omega-6 and omega-3 fatty acids in fetal programming. Clin Exp Pharmacol Physiol 2020; 47 (05) 907-915
    CrossrefPubMedSearch in Google Scholar
  • 10 Innes JK, Calder PC. Omega-6 fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids 2018; 132: 41-48
    CrossrefPubMedSearch in Google Scholar
  • 11 Smith SL, Rouse CA. Docosahexaenoic acid and the preterm infant. Matern Health Neonatol Perinatol 2017; 3: 22
    CrossrefPubMedSearch in Google Scholar
  • 12 Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol 2015; 27 (03) 200-215
    CrossrefPubMedSearch in Google Scholar
  • 13 Hadley KB, Ryan AS, Forsyth S, Gautier S, Salem Jr N. The essentiality of arachidonic acid in infant development. Nutrients 2016; 8 (04) 216
    CrossrefPubMedSearch in Google Scholar
  • 14 Robinson DT, Carlson SE, Murthy K, Frost B, Li S, Caplan M. Docosahexaenoic and arachidonic acid levels in extremely low birth weight infants with prolonged exposure to intravenous lipids. J Pediatr 2013; 162 (01) 56-61
    CrossrefPubMedSearch in Google Scholar
  • 15 Hellström A, Nilsson AK, Wackernagel D. et al. Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 2021; 175 (04) 359-367
    CrossrefPubMedSearch in Google Scholar
  • 16 Martin CR, Dasilva DA, Cluette-Brown JE. et al. Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are associated with neonatal morbidities. J Pediatr 2011; 159 (05) 743-749.e1 , 2
    CrossrefPubMedSearch in Google Scholar
  • 17 Calkins KL, Robinson DT. Intravenous lipid emulsions in the NICU. Neoreviews 2020; 21 (02) e109-e119
    CrossrefPubMedSearch in Google Scholar
  • 18 Zhang P, Lavoie PM, Lacaze-Masmonteil T, Rhainds M, Marc I. Omega-3 long-chain polyunsaturated fatty acids for extremely preterm infants: a systematic review. Pediatrics 2014; 134 (01) 120-134
    CrossrefPubMedSearch in Google Scholar
  • 19 Djuricic I, Calder PC. Beneficial outcomes of omega-6 and omega-3 polyunsaturated fatty acids on human health: an update for 2021. Nutrients 2021; 13 (07) 2421
    CrossrefPubMedSearch in Google Scholar
  • 20 Gordon A, Jeffery HE. Antibiotic regimens for suspected late onset sepsis in newborn infants. Cochrane Database Syst Rev 2005; 2005 (03) CD004501
    PubMedSearch in Google Scholar
  • 21 Gillespie TC, Kim ES, Grogan T, Tsui I, Chu A, Calkins KL. Decreased levels of erythrocyte membrane arachidonic and docosahexaenoic acids are associated with retinopathy of prematurity. Invest Ophthalmol Vis Sci 2022; 63 (12) 23
    CrossrefPubMedSearch in Google Scholar
  • 22 Bell MJ, Ternberg JL, Feigin RD. et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978; 187 (01) 1-7
    CrossrefPubMedSearch in Google Scholar
  • 23 Chiang MF, Quinn GE, Fielder AR. et al. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology 2021; 128 (10) e51-e68
    CrossrefPubMedSearch in Google Scholar
  • 24 Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92 (04) 529-534
    CrossrefPubMedSearch in Google Scholar
  • 25 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 (02) 377-381
    CrossrefPubMedSearch in Google Scholar
  • 26 Martin CR, Zaman MM, Gilkey C. et al. Resolvin D1 and lipoxin A4 improve alveolarization and normalize septal wall thickness in a neonatal murine model of hyperoxia-induced lung injury. PLoS One 2014; 9 (06) e98773
    CrossrefPubMedSearch in Google Scholar
  • 27 Wendel K, Aas MF, Gunnarsdottir G. et al. Effect of arachidonic and docosahexaenoic acid supplementation on respiratory outcomes and neonatal morbidities in preterm infants. Clin Nutr 2023; 42 (01) 22-28
    CrossrefPubMedSearch in Google Scholar
  • 28 Pastor N, Soler B, Mitmesser SH, Ferguson P, Lifschitz C. Infants fed docosahexaenoic acid- and arachidonic acid-supplemented formula have decreased incidence of bronchiolitis/bronchitis the first year of life. Clin Pediatr (Phila) 2006; 45 (09) 850-855
    CrossrefPubMedSearch in Google Scholar
  • 29 Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ. NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol 2003; 284 (01) L84-L89
    CrossrefPubMedSearch in Google Scholar
  • 30 Sharma D, Nkembi AS, Aubry E. et al. Maternal PUFA ω-3 supplementation prevents neonatal lung injuries induced by hyperoxia in newborn rats. Int J Mol Sci 2015; 16 (09) 22081-22093
    CrossrefPubMedSearch in Google Scholar
  • 31 Rogers LK, Valentine CJ, Pennell M. et al. Maternal docosahexaenoic acid supplementation decreases lung inflammation in hyperoxia-exposed newborn mice. J Nutr 2011; 141 (02) 214-222
    CrossrefPubMedSearch in Google Scholar
  • 32 Kul M, Gönül E, Akcan AB, Küçükodacı Z, Süleymanoğlu S. The effects of omega-3 fatty acids on the newborn rat hyperoxic lung injury. J Matern Fetal Neonatal Med 2020; 33 (14) 2434-2440
    CrossrefPubMedSearch in Google Scholar
  • 33 Ali M, Heyob KM, Velten M, Tipple TE, Rogers LK. DHA suppresses chronic apoptosis in the lung caused by perinatal inflammation. Am J Physiol Lung Cell Mol Physiol 2015; 309 (05) L441-L448
    CrossrefPubMedSearch in Google Scholar
  • 34 Tanaka K, Tanaka S, Shah N, Ota E, Namba F. Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2022; 35 (09) 1730-1738
    CrossrefPubMedSearch in Google Scholar
  • 35 van den Akker CHP, Onland W, van Kaam AH. Maternal docosahexaenoic acid supplementation and bronchopulmonary dysplasia in infants. JAMA 2020; 324 (20) 2104-2105
    CrossrefPubMedSearch in Google Scholar
  • 36 Manley BJ, Makrides M, Collins CT. et al; DINO Steering Committee. High-dose docosahexaenoic acid supplementation of preterm infants: respiratory and allergy outcomes. Pediatrics 2011; 128 (01) e71-e77
    CrossrefPubMedSearch in Google Scholar
  • 37 Marc I, Piedboeuf B, Lacaze-Masmonteil T. et al. Effect of maternal docosahexaenoic acid supplementation on bronchopulmonary dysplasia-free survival in breastfed preterm infants: a randomized clinical trial. JAMA 2020; 324 (02) 157-167
    CrossrefPubMedSearch in Google Scholar
  • 38 Kim ES, Lee LJ, Romero T, Calkins KL. Outcomes in preterm infants who received a lipid emulsion with fish oil: an observational study. JPEN J Parenter Enteral Nutr 2023; 47 (03) 354-363
    CrossrefPubMedSearch in Google Scholar
  • 39 Frazer LC, Martin CR. Parenteral lipid emulsions in the preterm infant: current issues and controversies. Arch Dis Child Fetal Neonatal Ed 2021; 106 (06) 676-681
    CrossrefPubMedSearch in Google Scholar
  • 40 Chan AP, Rostas S, Rogers S, Martin CR, Calkins KL. Parenteral nutrition in the neonatal intensive care unit: intravenous lipid emulsions. Clin Perinatol 2023; 50 (03) 575-589
    CrossrefPubMedSearch in Google Scholar
  • 41 Rayyan M, Devlieger H, Jochum F, Allegaert K. Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants. JPEN J Parenter Enteral Nutr 2012; 36 (1 Suppl): 81S-94S
    CrossrefPubMedSearch in Google Scholar
  • 42 Goulet O, Antébi H, Wolf C. et al. A new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: a single-center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr 2010; 34 (05) 485-495
    CrossrefPubMedSearch in Google Scholar
  • 43 Baack ML, Norris AW, Yao J, Colaizy T. Long-chain polyunsaturated fatty acid levels in US donor human milk: meeting the needs of premature infants?. J Perinatol 2012; 32 (08) 598-603
    CrossrefPubMedSearch in Google Scholar
  • 44 Jensen RG. Lipids in human milk. Lipids 1999; 34 (12) 1243-1271
    CrossrefPubMedSearch in Google Scholar
  • 45 Salem Jr N, Van Dael P. Arachidonic acid in human milk. Nutrients 2020; 12 (03) 626
    CrossrefPubMedSearch in Google Scholar
  • 46 Klem S, Klingler M, Demmelmair H, Koletzko B. Efficient and specific analysis of red blood cell glycerophospholipid fatty acid composition. PLoS ONE 2012; 7 (03) e33874
    CrossrefPubMedSearch in Google Scholar
  • 47 Lezo A, D'Onofrio V, Puccinelli MP. et al. Plasma and red blood cell PUFAs in home parenteral nutrition paediatric patients-effects of lipid emulsions. Nutrients 2020; 12 (12) 3748
    CrossrefPubMedSearch in Google Scholar